HRP20110503T1 - MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU - Google Patents

MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU Download PDF

Info

Publication number
HRP20110503T1
HRP20110503T1 HR20110503T HRP20110503T HRP20110503T1 HR P20110503 T1 HRP20110503 T1 HR P20110503T1 HR 20110503 T HR20110503 T HR 20110503T HR P20110503 T HRP20110503 T HR P20110503T HR P20110503 T1 HRP20110503 T1 HR P20110503T1
Authority
HR
Croatia
Prior art keywords
fgf receptor
fusion
soluble
modified fusion
soluble fgf
Prior art date
Application number
HR20110503T
Other languages
English (en)
Croatian (hr)
Inventor
Nesbit Mark
Cameron Batrice
Blanche Francis
Sordello Sylvie
Nicolazzi C�line
Trombe Marc
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110503(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20110503T1 publication Critical patent/HRP20110503T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20110503T 2006-11-28 2007-11-28 MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU HRP20110503T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (1)

Publication Number Publication Date
HRP20110503T1 true HRP20110503T1 (hr) 2011-08-31

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110503T HRP20110503T1 (hr) 2006-11-28 2007-11-28 MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU

Country Status (33)

Country Link
US (3) US8119770B2 (enExample)
EP (1) EP2092069B2 (enExample)
JP (1) JP2010510801A (enExample)
KR (1) KR20090102769A (enExample)
AR (1) AR063975A1 (enExample)
AT (1) ATE509106T1 (enExample)
AU (1) AU2007326985C1 (enExample)
BR (1) BRPI0719290A2 (enExample)
CA (1) CA2668932A1 (enExample)
CL (1) CL2007003411A1 (enExample)
CO (1) CO6190564A2 (enExample)
CR (1) CR10777A (enExample)
CY (1) CY1112435T1 (enExample)
DK (1) DK2092069T3 (enExample)
EA (1) EA018700B1 (enExample)
EC (1) ECSP099361A (enExample)
GT (1) GT200900137A (enExample)
HR (1) HRP20110503T1 (enExample)
IL (1) IL198480A0 (enExample)
MA (1) MA31143B1 (enExample)
MX (1) MX2009005692A (enExample)
MY (1) MY145914A (enExample)
NI (1) NI200900097A (enExample)
NO (1) NO20092414L (enExample)
PE (1) PE20081250A1 (enExample)
PL (1) PL2092069T3 (enExample)
PT (1) PT2092069E (enExample)
RS (1) RS51911B (enExample)
SI (1) SI2092069T1 (enExample)
SV (1) SV2009003272A (enExample)
TN (1) TN2009000184A1 (enExample)
TW (1) TW200839012A (enExample)
WO (1) WO2008065543A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
US8614183B2 (en) 2009-11-13 2013-12-24 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
NZ703786A (en) * 2010-11-15 2016-08-26 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
MX2013007421A (es) 2010-12-23 2014-02-03 Sanofi Sa Proteina de fusion robo1-fc para uso en el tratamiento del hepatocarcinoma.
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CN107823630A (zh) * 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
KR102420934B1 (ko) * 2013-03-11 2022-07-15 젠자임 코포레이션 과글리코실화된 결합 폴리펩티드
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
PE20160190A1 (es) 2013-08-01 2016-04-28 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
BR112018010410A8 (pt) * 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
CN110621336B (zh) 2017-05-16 2024-05-14 戊瑞治疗有限公司 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
AR114294A1 (es) 2017-11-30 2020-08-19 Grifols Diagnostic Solutions Inc Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1
US12448415B2 (en) * 2018-01-04 2025-10-21 Washington University Compositions and methods for inhibition of alphavirus infection
CR20200327A (es) * 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
EP3947458A1 (en) 2019-04-03 2022-02-09 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
DE69033109T2 (de) * 1989-07-06 1999-11-18 The Regents Of The University Of California, Oakland Rezeptoren für fibroblasten-wachstumsfaktoren
EP0529076B1 (en) * 1990-04-27 1995-12-06 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69133281T2 (de) 1990-07-06 2004-05-06 Gencell S.A. Rezeptoren der wachstumsfaktoren aus fibroblasten
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
WO2002002597A2 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2003085119A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
CA2499816C (en) * 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
JP2007525187A (ja) 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
JPWO2005035741A1 (ja) * 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins

Also Published As

Publication number Publication date
BRPI0719290A2 (pt) 2014-02-25
CA2668932A1 (en) 2008-06-05
DK2092069T3 (da) 2011-08-29
US20120195851A1 (en) 2012-08-02
CY1112435T1 (el) 2015-12-09
IL198480A0 (en) 2011-08-01
MX2009005692A (es) 2009-10-12
EA200970515A1 (ru) 2009-12-30
SV2009003272A (es) 2010-02-05
CO6190564A2 (es) 2010-08-19
EA018700B1 (ru) 2013-10-30
EP2092069B1 (en) 2011-05-11
CR10777A (es) 2009-07-23
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
MA31143B1 (fr) 2010-02-01
RS51911B (sr) 2012-02-29
PT2092069E (pt) 2011-07-29
US20100061979A1 (en) 2010-03-11
AU2007326985A1 (en) 2008-06-05
CL2007003411A1 (es) 2008-07-04
SI2092069T1 (sl) 2011-09-30
KR20090102769A (ko) 2009-09-30
AR063975A1 (es) 2009-03-04
MY145914A (en) 2012-05-15
AU2007326985C1 (en) 2014-02-20
EP2092069A2 (en) 2009-08-26
PL2092069T3 (pl) 2011-10-31
PE20081250A1 (es) 2008-10-07
EP2092069B2 (en) 2013-12-18
US8119770B2 (en) 2012-02-21
NO20092414L (no) 2009-08-21
WO2008065543A3 (en) 2008-08-14
AU2007326985B2 (en) 2013-08-15
GT200900137A (es) 2011-09-02
ATE509106T1 (de) 2011-05-15
WO2008065543A2 (en) 2008-06-05
NI200900097A (es) 2010-01-26
JP2010510801A (ja) 2010-04-08
US8481487B2 (en) 2013-07-09
TW200839012A (en) 2008-10-01
ECSP099361A (es) 2009-06-30

Similar Documents

Publication Publication Date Title
HRP20110503T1 (hr) MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU
JP2010510801A5 (enExample)
Ciardiello et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
Wester et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
Desnoyers et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
Harding et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer
Ciardiello et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
Ellis Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer
Morishige et al. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro
Libermann et al. An angiogenic growth factor is expressed in human glioma cells.
Gómez-Raposo et al. Angiogenesis and ovarian cancer
AU2008255527B2 (en) Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity
RU2013129450A (ru) Способ лечения опухолей с применением vegf-специфических антагонистов
Li et al. Cell transformation by fibroblast growth factors can be suppressed by truncated fibroblast growth factor receptors
CA3091140A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
DK1303602T3 (da) Oplöselige zalpha11 cytokinreceptorer
RU2010122934A (ru) Фармацевтическая композиция для лечения злокачественных опухолей
Askoxylakis et al. Peptide-based targeting of the platelet-derived growth factor receptor beta
RS54215B1 (sr) Sastavi i postupci za dijagnozu i tretman raka
DK1356046T3 (da) Cytokinreceptor zcytoR19
Zhao et al. Identification of a met-binding peptide from a phage display library
Kim et al. Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts
JP2011503039A5 (enExample)
Orlova et al. Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2: 342, a potential agent for imaging of HER2 expression in malignant tumors
Liu et al. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity